Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV open-label Egaten (triclabendazole) study in fascioliasis
2020-004200-33Phase 4
- Sponsor
- Novartis
- Start
- Jun 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of triclabendazole in fascioliasis, sponsored by Novartis. Primary endpoint: Safety and tolerability of Egaten (triclabendazole).
02
Drugs
triclabendazole
03
Conditions
fascioliasis
Beyond the preview
Go deeper on 2020-004200-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004200-33.